Skip to main content
. 2015 Dec 5;81(2):362–369. doi: 10.1111/bcp.12798

Table 5.

Treatment‐emergent adverse events by preferred term

All Subjects n = 12, n (%)
All treatment‐emergent adverse events 5 (41.7)
Fall * 2 (16.7)
Musculoskeletal pain 2 (16.7)
Upper respiratory tract infection 2 (16.7)
Diabetes mellitus * 1 (8.3)
Fatigue 1 (8.3)
Hypercholesterolaemia 1 (8.3)
Hypophosphatemia 1 (8.3)
Rectal haemorrhage * 1 (8.3)
Vertigo positional * 1 (8.3)

Preferred terms were coded using MedDRA version 16.1.

*

Not related to investigational product.